Product Pipeline
Our priority indications
Therapeutics
Pre-clin
Phase 1
Phase 2
Phase 3
NDA/BLA
Phase
Fezagepras (PBI-4050)
Respiratory Fibrotic Diseases e.g. Idiopathic Pulmonary Fibrosis (IPF)
GPR84 Antagonist
Undisclosed
Respiratory/GI
Undisclosed
NASH
Undisclosed
Kidney